Macías A.E.
139
Coauthors
10
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2007 | 2 |
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Cáncer | 15 |
| Farmacología | 3 |
| Inmunología | 2 |
| Medicina interna | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 12 |
| Farmacología y terapéutica | 7 |
| Medicina y salud | 3 |
| Mammalia | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 10 |
| Google Scholar | 1 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Carmen Elena Viada | 8 |
| Tania Crombet | 6 |
| Alfonso S. | 4 |
| Santiesteban Y. | 4 |
| De La Torre A.V. | 3 |
| Vázquez A.M. | 3 |
| Santiesteban E.R. | 3 |
| Pérez R. | 3 |
| Hernández M. | 3 |
| Mazorra Z. | 3 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Safety of racotumomab in the treatment of patients with non-small cell lung cancer
ArticleAbstract: In Cuba, lung cancer ranks second in incidence and first in mortality. Therefore, it is necessary toPalabras claves:Adverse events, Clinical trial, Non-small cell lung cancer, RacotumomabAutores:Carmen Elena Viada, Estevez D., Gastón Y., Macías A.E., Pérez Ruiz L.Fuentes:scopusNimotuzumab for the treatment of patients with malignant glioma. Comparison between pre-registration and post-approved studies
ArticleAbstract: Nimotuzumab is a monoclonal antibody targeted against the epidermal growth factor receptor approvedPalabras claves:And High-grade glioma, Controlled clinical studies, nimotuzumab, Postmarking studies, Target therapiesAutores:Aliuska Frías, Carmen Elena Viada, García L., Luaces P.L.o., Mabel Álvarez, Macías A.E., Santiesteban Y., Saurez G., Tania CrombetFuentes:scopusEvaluation of racotumomab for the treatment of lung cancer: Meta-analysis of controlled trials of the CIM
ArticleAbstract: Racotumomab is a therapeutic cancer vaccine entirely developed in Cuba and licensed in the country fPalabras claves:immunotherapy, Non-small cell lung cancer, Oncological vaccines, Racotumomab, Vaccinal treatmentAutores:Alfonso S., Aliuska Frías, Ballesteros J., Carmen Elena Viada, Hernández M., Mabel Álvarez, Macías A.E., Martha M. Fors-López, Quintero J., Robaina M.Fuentes:scopusEvaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusSecurity 1E10 anti-idiotypic vaccine in patients with tumors of different locations
ArticleAbstract: Cancer is a leading cause of death in Cuba and the world. Lung cancer is the leading cause of death,Palabras claves:Anti-idiotypic, Breast, Cáncer, COLON, Non-small cell lung vaccine, security, Small cell lungAutores:Alfonso S., Carmen Elena Viada, García E., Guerra P.P., Hernández M., Macías A.E., MARTHA FORS, Martha M. Fors-López, Mendoza I.C., Neninger Vinageras E., Pérez Ruiz L., Santiesteban E.R., Vázquez A.M.Fuentes:googlescopus